Published • loading... • Updated
A cancer vaccine is closer than ever
Jarvis says recent scientific advances have made a personalized vaccine approach closer to reality, with researchers still testing how well it works.
- Merck & Co. and Moderna Inc. are moving cancer vaccine research beyond the "hope" and "promise" phases, Bloomberg columnist Jarvis writes, developing personalized treatments to help the immune system identify and destroy cancer cells.
- By genetically sequencing a patient's tumor, scientists identify mutations and create personalized mRNA strands that teach the immune system to recognize and destroy cancer cells.
- Combining personalized vaccines with the immunotherapy drug Keytruda has shown success in preventing recurrence; Michael of Memorial Sloan noted that adding the vaccine to treatment is a "quite a big achievement."
- Researchers are now shifting focus toward starting immunotherapy before surgery to keep the disease at bay, aiming to help the immune system recognize and destroy cancer cells more effectively than previous post-surgical approaches.
- Despite promising early findings, developers must still convince medical science skeptics that these vaccines work, as ongoing research aims to prove these treatments can effectively target difficult tumors, such as pancreatic cancer.
Insights by Ground AI
15 Articles
15 Articles
Coverage Details
Total News Sources15
Leaning Left2Leaning Right1Center12Last UpdatedBias Distribution80% Center
Bias Distribution
- 80% of the sources are Center
80% Center
13%
C 80%
Factuality
To view factuality data please Upgrade to Premium
